GlaxoSmithKline News and Research

RSS

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Regulus Therapeutics Inc. announced today that advancements from its leading microRNA platform and product pipeline were presented at the "6th Annual Meeting of the Oligonucleotide Therapeutics Society" held October 20 - 23, 2010 in Dana Point, California.

22 Oct 2010

Dicerna secures $4 million in second closing of Series B equity financing

Dicerna Pharmaceuticals, Inc. a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced a second closing of its Series B equity financing, securing an additional $4 million and bringing the total capital raised in this round to $29 million.

22 Oct 2010

Genmab A/S reports DKK 78 million in net sales for Arzerra

Genmab A/S announced today that the net sales for Arzerra(R) (ofatumumab) during the third quarter of 2010 were approximately DKK 78 million (approximately USD 14 million).

21 Oct 2010

Victorian Government grants assist companies build global markets

The Brumby Labor Government is providing $410,000 in grants to help three Melbourne companies improve their global competitiveness, save money on production costs and create local jobs.

21 Oct 2010

Also in Global Health News: Foreign aid in Ethiopia; Elizabeth Glaser Pediatric AIDS Foundation; Health in Myanmar; Poverty in Zambia; Rwanda's progress on MDGs; Men involved in PMTCT of HIV

Ethiopia's government has been restricting access to food and other types of foreign aid among opposition supporters, Human Rights Watch (HRW) said in a report on Tuesday, Reuters reports (Malone, 10/19). The report is based on more than 200 interviews, conducted over a six-month period in 2009, of people in 53 villages across three regions of the country, according to an HRW press release (10/19).

21 Oct 2010

ADHA and GSK emphasize importance of proper brushing as key to maintaining oral health

With the theme "Healthy Habits are Easier than You Think" for its National Dental Hygiene Month (NDHM) celebration this October, the American Dental Hygienists' Association (ADHA), in collaboration with GlaxoSmithKline (GSK), makers of Aquafresh®, emphasizes the importance of proper brushing as a key to maintaining excellent oral health.

19 Oct 2010

MPI of Biochemistry and GSK collaborate in development of new drugs for type 2 diabetes

The recently signed cooperation agreement between the MPI of Biochemistry and GSK pursues the objective of developing innovative new drugs. The joint research and development work is based on the research findings of Axel Ullrich, Director at the MPI of Biochemistry.

19 Oct 2010

Issuing first report on NTDS, WHO aims for 'complete control' by 2015

The WHO said on Thursday that it was aiming for 'complete control' by 2015 of tropical diseases that affect one billion impoverished people and kill an estimated 534,000 people each year, Agence France-Presse reports.

15 Oct 2010

GSK to expand donation of albendazole medicine to treat children with STH risk

At the launch of the World Health Organization's (WHO) first report on Neglected Tropical Diseases today, GSK announced a new five year commitment to expand the donation of its medicine albendazole to treat children at risk of intestinal worms, known as soil-transmitted helminths (STH).

14 Oct 2010

Prosensa receives £7.5M milestone payment in GSK2402968 Phase IIa trial for DMD

Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, has announced that it received a £7.5m milestone payment from GlaxoSmithKline (GSK) as a result of achieving a data milestone in its Phase IIa open label extension trial of GSK2402968 (PRO051), being developed to treat Duchenne Muscular Dystrophy (DMD) under its agreement with GSK. The milestone payment was based upon achievement of a successful safety review, with no serious safety signals observed.

13 Oct 2010

Meridia – weight loss pill off the shelves in US

Abbott Pharmaceuticals has announced the withdrawal of weight loss drug Meridia from shelves in the United States and urged patients to stop taking it after regulators questioned its safety. The withdrawal happened last Friday in the US. In January, Meridia sales were suspended in Europe.

10 Oct 2010

NIH announces it will share IP rights to some AIDS drugs in UNITAID Patent Pool

The NIH announced Thursday it will share intellectual property rights on some AIDS drugs in a patent pool designed to make treatments more widely available to the poor, Reuters reports.

4 Oct 2010

Herpevac Trial for Women finds experimental vaccine ineffective in prevention of genital herpes disease

An experimental vaccine intended to prevent genital herpes disease in women, although generally safe and well-tolerated, proved ineffective when tested in the recently concluded clinical study known as the Herpevac Trial for Women.

1 Oct 2010

Cardium expands wound healing and tissue regeneration portfolio

Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

30 Sep 2010

Malaria experts focus on RTS, S as Malaria Vaccines for the World Conference begins

Scientists and physicians from around the world gathered in Washington, D.C. on Tuesday for the start of the second Malaria Vaccines for the World Conference, SAPA/News24 reports.

30 Sep 2010

Malaria vaccine close to reality

A successful and effective malaria vaccine could be available in Africa by 2015 revealed a co-inventor of the shot against the killer disease, Tuesday. Advance trials of the RTS,S vaccine against falciparum malaria are under way in seven African countries. This variety of malaria is the deadliest and trials are said to be showing encouraging results according to GlaxoSmithKline researcher Joe Cohen, who has been working on developing the vaccine for over 20 years.

29 Sep 2010

Malaria vaccine development meeting begins in Washington

Agence France-Presse reports on a malaria vaccine development meeting that kicks off Tuesday in Washington, D.C.One of the stars at the meeting will be the RTS,S malaria vaccine, which has been developed by GlaxoSmithKline and the PATH Malaria Vaccine Initiative, with funding from the Bill & Melinda Gates Foundation, the news service writes.

29 Sep 2010

GSK supports AHA policy statement on smokeless tobacco products

GlaxoSmithKline (GSK) Consumer Healthcare, a leader in helping smokers quit and the marketer of nicotine replacement therapy (NRT) products, including Nicorette and NicoDerm CQ, supports the findings of the American Heart Association (AHA) policy statement regarding smokeless tobacco products.

28 Sep 2010

FDA, European regulators restrict Avandia use

The Food and Drug Administration and European regulators said they were taking action on Avandia, made by GlaxoSmithKline PLC, because of data tying it to increased risk of heart attacks.

27 Sep 2010

EMA, FDA announce regulatory decisions on Avandia drug

GlaxoSmithKline confirms that following a review of Avandia (rosiglitazone maleate) by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), each agency has today announced their individual regulatory decisions and the resulting actions.

24 Sep 2010